Frexalimab, an experimental anti-CD40L antibody therapy from Sanofi, significantly reduced the number of new brain lesions with active inflammation…
Articles by Lindsey Shapiro, PhD
The National Multiple Sclerosis Society has awarded Clene Nanomedicine a grant to advance its treatment candidate CNM-Au8 for…
Vidofludimus calcium (IMU-838), an investigational multiple sclerosis (MS) therapy with promising results in clinical trials, may exert neuroprotective…
A more pro-inflammatory diet is associated with a higher risk of relapses and more inflammatory brain lesions for multiple…
Surgical procedures to treat trigeminal neuralgia — a type of nerve damage that causes facial pain — may be…
A four-month home-based aerobic walking program was feasible and may help improve cognitive function for multiple sclerosis (MS) patients,…
Tysabri (natalizumab) is generally safe and effectively lowers disease activity in people with multiple sclerosis (MS), according to…
Clusters of immunoglobulin G (IgG) antibodies in the blood of multiple sclerosis (MS) patients appear to contribute to the nerve…
About 2.5 years of treatment with tolebrutinib was associated with low relapse rates and stable disability levels among people…
Multiple sclerosis (MS) patients with greater psychological resilience — a better ability to cope with and recover quickly from…
OCH, a molecule designed to have beneficial effects on immune regulation in multiple sclerosis (MS), led to increases in…
OCS-05, a neuroprotective treatment candidate being developed by Oculis for multiple sclerosis (MS) or other causes of…
Real-world use of nabiximols, an oral spray cannabinoid treatment, was associated with a self-reported easing of spasticity and related…
A bacterial toxin in the gut — specifically, the epsilon toxin produced by Clostridium perfringens bacteria in the intestinal tract —…
Treatment with InnoCare Pharma’s orelabrutinib — an experimental inhibitor of the Bruton’s tyrosine kinase (BTK) enzyme — led to…
An upcoming study will investigate how well icobrain MS, an artificial intelligence (AI)-based technology, can interpret MRI data from people with…
A new study of women with multiple sclerosis (MS) who had previously given birth may have identified one of…
GA Depot, an experimental long-acting version of glatiramer acetate, significantly reduced relapse rates and prevented the development of new…
New data from a Phase 2 clinical trial testing vidofludimus calcium, Immunic Therapeutics’ novel oral treatment candidate for…
Multiple sclerosis (MS) has long been considered a disease that mostly affects white women. But in the U.S., the…
Activating certain receptors on astrocytes — a type of nerve support cell — may offer a way of treating cognitive…
Limiting calorie intake over two days of each week for three months led to beneficial immune and metabolic changes, as…
A greater loss of myelin — the protective coating around nerve fibers — in the part of the spinal…
A certain bacterial species is enriched in the gut of people with secondary progressive multiple sclerosis (SPMS) and may…
Psychiatric symptoms such as depression and anxiety are more common among multiple sclerosis (MS) patients in the five years…
Changes in mitochondria — cells’ energy production centers — are evident in early disease stages in a mouse model of…
The aryl hydrocarbon receptor (AHR) may facilitate or “tune” the crosstalk between the gut microbiome and the immune responses that…
Eating too much salt can disrupt the energy metabolism of regulatory T-cells (Tregs), which normally work to control inflammation and…
The multiple sclerosis (MS) community is gearing up for the eighth annual Americas Committee for Treatment and Research in…
Tascenso ODT, an approved alternative to Gilenya (fingolimod), is now available to multiple sclerosis (MS) patients in the…